Danilo del Campo, MD
Dermatology · Chicago, ILNPI 1922340405
Payments from drug & device makers
Across 971 payments — averaging $111.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$65K
- Sun Pharmaceutical Industries Inc.$21K
- EPI Health, LLC$3K
- Johnson & Johnson$3K
- AbbVie$3K
- Medimetriks Pharmaceuticals, Inc.$2K
- plus $9K from 26 others
What the payments were for
- Consulting fees$14,22313%
- Speaking & faculty fees$75,27270%
- Travel & lodging$2,0982%
- Food & beverage$15,62514%
- Education$6921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 106 | $65,423 |
| Sun Pharmaceutical Industries Inc. | 72 | $21,491 |
| EPI Health, LLC | 5 | $3,366 |
| Johnson & Johnson | 101 | $3,315 |
| AbbVie | 155 | $3,033 |
| Medimetriks Pharmaceuticals, Inc. | 18 | $2,240 |
| LEO Pharma Inc. | 43 | $1,570 |
| Amgen | 68 | $1,472 |
| Pfizer | 94 | $880 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 63 | $870 |
| Mayne Pharma Commercial LLC | 40 | $609 |
| Lilly USA, LLC | 34 | $502 |
| Journey Medical Corporation | 42 | $427 |
| Novartis | 16 | $347 |
| Bristol Myers Squibb | 12 | $315 |
| Regeneron Healthcare Solutions, Inc. | 13 | $315 |
| UCB, Inc. | 12 | $313 |
| Incyte Corporation | 11 | $295 |
| Sanofi | 9 | $175 |
| VYNE Pharmaceuticals Inc. | 16 | $168 |
| Janssen Scientific Affairs, LLC | 1 | $132 |
| E.r. Squibb & Sons, L.L.C. | 7 | $124 |
| Prugen, Inc. Pharmaceuticals | 13 | $121 |
| Arcutis Biotherapeutics, Inc. | 5 | $87 |
| Revance Therapeutics, Inc. | 1 | $86 |
| Taro Pharmaceuticals USA, Inc. | 4 | $79 |
| Botanix SB Inc | 3 | $53 |
| Encore Dermatology Inc. | 3 | $48 |
| Almirall LLC | 1 | $17 |
| Aclaris Therapeutics, Inc. | 1 | $17 |
| Mission Pharmacal Company | 1 | $17 |
| Organon | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEMLUVIO$46,978
- ILUMYA$17,225
- WYNZORA$3,300
- Halog$3,162
- Tremfya$1,863
- Clindacin ETZ$1,500
- ADBRY$990
- Neo-Synalar$500
- Tovet (emollient formulation)$500
- Sumadan Wash$500
- Otezla$334
- Skyrizi$327
- Rinvoq$229
- Humira$108
How this compares
$107,910 in reported general payments places this provider in the 90th percentile of 606 dermatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SkyriziRisankizumab-Rzaa | 17 | $340,980 |
| TremfyaGuselkumab | 11 | $157,199 |
| Dupixent PenDupilumab | 25 | $92,740 |
| OtezlaApremilast | 19 | $87,138 |
| Clobetasol Propionate | 99 | $6,726 |
| Triamcinolone Acetonide | 359 | $6,394 |
| Fluocinonide | 51 | $3,078 |
| Metronidazole | 30 | $1,876 |
| Betamethasone Dipropionate | 39 | $1,789 |
| Ketoconazole | 107 | $1,297 |
| Doxycycline Hyclate | 73 | $1,157 |
| Clindamycin Phosphate | 50 | $1,126 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 33 | $838 |
| Gentamicin Sulfate | 27 | $781 |
| Hydrocortisone | 114 | $667 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSkyrizi | $3,033 | $340,98017 claims |
| Johnson & JohnsonTremfya | $3,315 | $157,19911 claims |
| AmgenOtezla | $1,472 | $87,13819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 606 dermatology providers in Illinois.
Other dermatology in Chicago
- Raj ChovatiyaChicago$3.7M
- Peter LioChicago$2.5M
- Elizabeth KiracofeChicago$1.6M
- Walter LiszewskiChicago$1.2M
- Maria ColavincenzoChicago$627K
- Carolyn JacobChicago$606K
- Roopal KunduChicago$498K
- Sarah ChamlinChicago$415K
- Omer IbrahimChicago$313K
- Joaquin BrievaChicago$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.